Galectin Therapeutics Files 8-K on Financials

TL;DR

GALECTIN THERAPEUTICS FILED 8-K ON 3/31/26 WITH FINANCIALS.

AI Summary

Galectin Therapeutics Inc. filed an 8-K on March 31, 2026, reporting on its results of operations and financial condition for the period ending March 31, 2026. The filing includes financial statements and exhibits, with the primary document being an iXBRL formatted 8-K report.

Why It Matters

This 8-K filing provides investors with crucial updates on Galectin Therapeutics' financial performance and operational status as of March 31, 2026.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial results and does not indicate any immediate or significant new risks.

Key Players & Entities

• Galectin Therapeutics Inc. (company) — Filer of the 8-K report
• 0001133416 (company) — CIK number for Galectin Therapeutics Inc.
• 2026-03-31 (date) — Period of report and filing date

FAQ

Key Financial Figures

• $0.001 — hange on which registered Common Stock $0.001par value per share GALT The Nasdaq

Filing Documents

• ef20068722_8k.htm (8-K) — 31KB
• ef20068722_ex99-1.htm (EX-99.1) — 79KB
• image00001.jpg (GRAPHIC) — 5KB
• 0001140361-26-012158.txt ( ) — 256KB
• galt-20260331.xsd (EX-101.SCH) — 4KB
• galt-20260331_lab.xml (EX-101.LAB) — 21KB
• galt-20260331_pre.xml (EX-101.PRE) — 16KB
• ef20068722_8k_htm.xml (XML) — 4KB

02

Item 2.02 Results of Operations and Financial Condition. On March 31, 2026, Galectin Therapeutics Inc. ("Galectin Therapeutics") issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 31, 2026 (the "Press Release"), a copy of which is attached hereto as Exhibit 99.1. Except for the historical information contained in this report, the statements made by Galectin Therapeutics are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Galectin Therapeutics' future financial performance could differ significantly from the expectations of management and from results expressed or implied in the Press Release. Forward-looking statements in the Press Release are subject to certain risks and uncertainties described in the Press Release. For further information on other risk factors, please refer to the "Risk Factors" contained in Galectin Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission, and its subsequent filings with the SEC . The information in this Item 2.02 is being furnished, not filed, pursuant to Item 2.02 of Form 8-K. Accordingly, the information in Item 2.02 of this report, including the Press Release attached hereto as Exhibit 99.1, will not be incorporated by reference into any registration statement filed by Galectin under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated March 31, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: March 31, 2026 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR